Orchid Pharma Ltd
NSE:ORCHPHARMA

Watchlist Manager
Orchid Pharma Ltd Logo
Orchid Pharma Ltd
NSE:ORCHPHARMA
Watchlist
Price: 789.35 INR -4.75%
Market Cap: 40B INR

Intrinsic Value

The intrinsic value of one ORCHPHARMA stock under the Base Case scenario is 1 175.19 INR. Compared to the current market price of 789.35 INR, Orchid Pharma Ltd is Undervalued by 33%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ORCHPHARMA Intrinsic Value
1 175.19 INR
Undervaluation 33%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Orchid Pharma Ltd

ORCHPHARMA
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for ORCHPHARMA cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Orchid Pharma Ltd
NSE:ORCHPHARMA
IN
Pharmaceuticals
Market Cap
40B INR
IPO
Sep 6, 1993
IN
Pharmaceuticals
Market Cap
40B INR
IPO
Sep 6, 1993
Price
â‚ąfalse
EPS
â‚ąfalse
Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ORCHPHARMA?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Orchid Pharma Ltd
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Orchid Pharma Ltd

Current Assets 8.3B
Cash & Short-Term Investments 2.5B
Receivables 2.2B
Other Current Assets 3.7B
Non-Current Assets 8B
Long-Term Investments 525.1m
PP&E 6.6B
Intangibles 185.9m
Other Non-Current Assets 745.3m
Efficiency

Free Cash Flow Analysis
Orchid Pharma Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Orchid Pharma Ltd

Revenue
9B INR
Cost of Revenue
-5.3B INR
Gross Profit
3.7B INR
Operating Expenses
-2.8B INR
Operating Income
932.9m INR
Other Expenses
262.6m INR
Net Income
1.2B INR
Fundamental Scores

ORCHPHARMA Profitability Score
Profitability Due Diligence

Orchid Pharma Ltd's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
ROE is Increasing
54/100
Profitability
Score

Orchid Pharma Ltd's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

ORCHPHARMA Solvency Score
Solvency Due Diligence

Orchid Pharma Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Short-Term Solvency
82/100
Solvency
Score

Orchid Pharma Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ORCHPHARMA Price Targets Summary
Orchid Pharma Ltd

Wall Street analysts forecast ORCHPHARMA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ORCHPHARMA is 1 532.72 INR with a low forecast of 1 105.95 INR and a high forecast of 1 935.15 INR.

Lowest
Price Target
1 105.95 INR
40% Upside
Average
Price Target
1 532.72 INR
94% Upside
Highest
Price Target
1 935.15 INR
145% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for ORCHPHARMA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ORCHPHARMA Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ORCHPHARMA stock?

The intrinsic value of one ORCHPHARMA stock under the Base Case scenario is 1 175.19 INR.

Is ORCHPHARMA stock undervalued or overvalued?

Compared to the current market price of 789.35 INR, Orchid Pharma Ltd is Undervalued by 33%.

Back to Top